Dr U'Prichard joins Ocimum's board
This article was originally published in Scrip
David U'Prichard, president of Druid Consulting LLC, has joined the board of Ocimum Biosolutions, a genomics solutions company in India. Dr U'Prichard holds board positions in several companies including Life Technologies, Oxagen, Cyclacel and Silence Therapeutics. He is also a partner at Red Abbey Venture Partners, and was chairman of R&D at SmithKline Beecham from 1997 to 1999, among other senior positions he has held in prior stints in the industry.
You may also be interested in...
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.
Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.